Therapeutic options for recurrent malignant glioma

Radiotherapy and Oncology

Volumn 98, Issue 1, 2011, Pages 1-14

  Niyazi, Maximilian ^a   Siefert, Axel ^a   Schwarz, Silke Birgit ^a   Ganswindt, Ute ^a   Kreth, Friedrich Wilhelm ^a   Tonn, Jörg Christian ^a   Belka, Claus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bevacizumab; Malignant glioma; Radiotherapy; Relapse; Temozolomide

Indexed keywords

ATRASENTAN; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CELECOXIB; CILENGITIDE; CISPLATIN; CYCLOPHOSPHAMIDE; CYSTEMUSTINE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FOTEMUSTINE; GEFITINIB; IFOSFAMIDE; IRINOTECAN; LENALIDOMIDE; LOMUSTINE; MITOXANTRONE; NIMUSTINE; PACLITAXEL; RETINOIC ACID; TEMOZOLOMIDE; TENIPOSIDE; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; VORINOSTAT;

ALOPECIA; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; FATIGUE; GLIOBLASTOMA; GRANULOCYTOPENIA; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOXIA; INFECTION; INTESTINE PERFORATION; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTRON CAPTURE THERAPY; NEUTROPENIA; PARANOID PSYCHOSIS; PERIPHERAL EDEMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; RASH; RECURRENT CANCER; REOPERATION; REVIEW; SALVAGE THERAPY; STEREOTAXIC SURGERY; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT INDICATION; TUMOR BLEEDING; WOUND DEHISCENCE;

EID: 78651362626     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.11.006     Document Type: Review

References (175)

1. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996 (Pubitemid 40349501)
2. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
3. R. Bashir, F. Hochberg, and R. Oot Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields Neurosurgery 23 1988 27 30
4. E.P. Jansen, L.G. Dewit, M. van Herk, and H. Bartelink Target volumes in radiotherapy for high-grade malignant glioma of the brain Radiother Oncol 56 2000 151 156 (Pubitemid 30601671)
5. K.E. Wallner, J.H. Galicich, G. Krol, E. Arbit, and M.G. Malkin Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma Int J Radiat Oncol Biol Phys 16 1989 1405 1409 (Pubitemid 19154322)
6. H. Aydin, I. Sillenberg, and H. von Lieven Patterns of failure following CT-based 3-D irradiation for malignant glioma Strahlenther Onkol 177 2001 424 431 (Pubitemid 32756556)
7. P.K. Sneed, P.H. Gutin, and D.A. Larson Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost Int J Radiat Oncol Biol Phys 29 1994 719 727
8. M.C. Chamberlain, and P.A. Kormanik Practical guidelines for the treatment of malignant gliomas West J Med 168 1998 114 120 (Pubitemid 28100970)
9. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon 2nd Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729 (Pubitemid 350086473)
10. M. Weller Diagnostic and therapeutic strategies for recurrent gliomas Aktuelle Neurol 34 2007 564 569 (Pubitemid 351396820)
11. J.R. Perry, P. Rizek, R. Cashman, M. Morrison, and T. Morrison Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach Cancer 113 2008 2152 2157
12. E.R. Laws, I.F. Parney, and W. Huang Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project J Neurosurg 99 2003 467 473 (Pubitemid 37040405)
13. M. Salcman Resection and reoperation in neuro-oncology. Rationale and approach Neurol Clin 3 1985 831 842 (Pubitemid 16028841)
14. R.P. Moser Surgery for glioma relapse. Factors that influence a favorable outcome Cancer 62 1988 381 390
15. G.Rt. Harsh, V.A. Levin, P.H. Gutin, M. Seager, P. Silver, and C.B. Wilson Reoperation for recurrent glioblastoma and anaplastic astrocytoma Neurosurgery 21 1987 615 621 (Pubitemid 18001497)
16. M. Ammirati, J.H. Galicich, E. Arbit, and Y. Liao Reoperation in the treatment of recurrent intracranial malignant gliomas Neurosurgery 21 1987 607 614 (Pubitemid 18001496)
17. E.S. Mandl, C.M. Dirven, D.R. Buis, T.J. Postma, and W.P. Vandertop Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy Surg Neurol 69 2008 506 509 [discussion 509]
18. P. Dirks, M. Bernstein, P.J. Muller, and W.S. Tucker The value of reoperation for recurrent glioblastoma Can J Surg 36 1993 271 275 (Pubitemid 23248140)
19. F.G. Barker 2nd, S.M. Chang, and P.H. Gutin Survival and functional status after resection of recurrent glioblastoma multiforme Neurosurgery 42 1998 709 720 [discussion 720-703]
20. M. Pinsker, and C. Lumenta Experiences with reoperation on recurrent glioblastoma multiforme Zentralbl Neurochir 62 2001 43 47 (Pubitemid 34083899)
21. G.M. Barbagallo, M.D. Jenkinson, and A.R. Brodbelt 'Recurrent' glioblastoma multiforme, when should we reoperate? Br J Neurosurg 22 2008 452 455
22. J. Guyotat, F. Signorelli, D. Frappaz, G. Madarassy, A.C. Ricci, and P. Bret Is reoperation for recurrence of glioblastoma justified? Oncol Rep 7 2000 899 904
23. S.E. Combs, S. Gutwein, C. Thilmann, P. Huber, J. Debus, and D. Schulz-Ertner Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme J Neurooncol 74 2005 167 171 (Pubitemid 41478913)
24. S.E. Combs, V. Widmer, C. Thilmann, H. Hof, J. Debus, and D. Schulz-Ertner Stereotactic radiosurgery (SRS) - treatment option for recurrent glioblastoma multiforme (GBM) Cancer 104 2005 2168 2173 (Pubitemid 41579963)
25. T. Biswas, P. Okunieff, and M.C. Schell Stereotactic radiosurgery for glioblastoma: retrospective analysis Radiat Oncol 4 2009 11
26. C.D. Fuller, M. Choi, and B. Forthuber Standard fractionation intensity modulated radiation therapy (IMRT) of primary, recurrent glioblastoma multiforme Radiat Oncol 2 2007 26
27. K.K. Ang, R.E. Price, and L.C. Stephens The tolerance of primate spinal-cord to reirradiation Int J Radiat Oncol Biol Phys 25 1993 459 464
28. S.E. Combs, J. Debus, and D. Schulz-Ertner Radiotherapeutic alternatives for previously irradiated recurrent gliomas BMC Cancer 2007 7 (Pubitemid 351165862)
29. E. Fokas, U. Wacker, M.W. Gross, M. Henzel, E. Encheva, and R. Engenhart-Cabillic Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 185 2009 235 240
30. A. Ernst-Stecken, O. Ganslandt, U. Lambrecht, R. Sauer, and G. Grabenbauer Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma J Neurooncol 81 2007 287 294 (Pubitemid 46165333)
31. G. Henke, F. Paulsen, and J.P. Steinbach Hypofractionated reirradiation for recurrent malignant glioma Strahlenther Onkol 185 2009 113 119
32. S.E. Combs, C. Thilmann, L. Edler, J. Debus, and D. Schulz-Ertner Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution J Clin Oncol 23 2005 8863 8869 (Pubitemid 46211533)
33. D. Vordermark, O. Kolbl, K. Ruprecht, G.H. Vince, K. Bratengeier, and M. Flentje BMC Cancer 5 2005 55
34. A.L. Grosu, W.A. Weber, and M. Franz Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy Int J Radiat Oncol Biol Phys 63 2005 511 519 (Pubitemid 41317169)
35. A.-L. Grosu, and W.A. Weber PET for radiation treatment planning of brain tumours Radiother Oncol 96 2010 325 327
36. J. Ma, Z. Chang, Z. Wang, Q.J. Wu, J.P. Kirkpatrick, and F.-F. Yin Degree-of-freedom image-guidance for intracranial non-invasive stereotactic radiotherapy: comparison with kilo-voltage cone-beam CT Radiother Oncol 93 2009 602 608
37. R. Mayer, and P. Sminia Reirradiation tolerance of the human brain Int J Radiat Oncol Biol Phys 70 2008 1350 1360 (Pubitemid 351417752)
38. Y.R. Lawrence, X.A. Li, and I. el Naqa Radiation dose-volume effects in the brain Int J Radiat Oncol Biol Phys 76 2010 S20 S27
39. C. Mayo, M.K. Martel, L.B. Marks, J. Flickinger, J. Nam, and J. Kirkpatrick Radiation dose-volume effects of optic nerves and chiasm Int J Radiat Oncol Biol Phys 76 2010 S28 S35
40. C. Mayo, E. Yorke, and T.E. Merchant Radiation associated brainstem injury Int J Radiat Oncol Biol Phys 76 2010 S36 S41
41. B. Emami, J. Lyman, and A. Brown Tolerance of normal tissue to therapeutic irradiation Int J Radiat Oncol Biol Phys 21 1991 109 122
42. D.S. Kong, J.I. Lee, K. Park, J.H. Kim, D.H. Lim, and D.H. Nam Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas Cancer 112 2008 2046 2051 (Pubitemid 351574081)
43. W.A. Hall, H.R. Djalilian, and P.W. Sperduto Stereotactic radiosurgery for recurrent malignant gliomas J Clin Oncol 13 1995 1642 1648
44. D. Kondziolka, J.C. Flickinger, D.J. Bissonette, M. Bozik, and L.D. Lunsford Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms Neurosurgery 41 1997 776 783 [discussion 783-775] (Pubitemid 27422104)
45. J.E. Masciopinto, A.B. Levin, M.P. Mehta, and B.S. Rhode Stereotactic radiosurgery for glioblastoma: a final report of 31 patients J Neurosurg 82 1995 530 535
46. K.H. Cho, W.A. Hall, B.J. Gerbi, P.D. Higgins, W.A. McGuire, and H.B. Clark Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas Int J Radiat Oncol Biol Phys 45 1999 1133 1141
47. M. Patel, F. Siddiqui, and J.Y. Jin Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival J Neurooncol 92 2009 185 191
48. J.Y. Jin, F.F. Yin, S. Ryu, M. Ajlouni, and J.H. Kim Dosimetric study using different leaf-width MLCs for treatment planning of dynamic conformal arcs and intensity-modulated radiosurgery Med Phys 32 2005 405 411 (Pubitemid 40322321)
49. R.W. Laing, A.P. Warrington, J. Graham, J. Britton, F. Hines, and M. Brada Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (phase I/II study) Radiother Oncol 27 1993 22 29 (Pubitemid 23180137)
50. S.F. Shepherd, R.W. Laing, and V.P. Cosgrove Hypofractionated stereotactic radiotherapy in the management of recurrent glioma Int J Radiat Oncol Biol Phys 37 1997 393 398 (Pubitemid 27138724)
51. G. Lederman, E. Arbit, M. Odaimi, S. Wertheim, and E. Lombardi Recurrent glioblastoma multiforme: potential benefits using fractionated stereotactic radiotherapy and concurrent taxol Stereotact Funct Neurosurg 69 1997 162 174 (Pubitemid 28305437)
52. G. Lederman, M. Wronski, and E. Arbit Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel Am J Clin Oncol 23 2000 155 159
53. G. Lederman, E. Arbit, M. Odaimi, E. Lombardi, M. Wrzolek, and M. Wronski Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: a preliminary report Int J Radiat Oncol Biol Phys 40 1998 661 666 (Pubitemid 28104237)
54. M. Arcicasa, M. Roncadin, E. Bidoli, A. Dedkov, M. Gigante, and M.G. Trovo Reirradiation and lomustine in patients with relapsed high-grade gliomas Int J Radiat Oncol Biol Phys 43 1999 789 793 (Pubitemid 29152651)
55. J. Glass, C.L. Silverman, R. Axelrod, B.W. Corn, and D.W. Andrews Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma Am J Clin Oncol 20 1997 226 229 (Pubitemid 27221038)
56. L. VanderSpek, B. Fisher, G. Bauman, and D. Macdonald 3D conformal radiotherapy and cisplatin for recurrent malignant glioma Can J Neurol Sci 35 2008 57 64 (Pubitemid 351518289)
57. S.E. Combs, M. Bischof, and T. Welzel Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas J Neurooncol 89 2008 205 210
58. S.E. Combs, J. Wagner, D. Schulz-Ertner, M. Bischof, and J. Debus Re-irradiation using high-precision radiotherapy and concomitant temozolomide in patients with recurrent glioma Neurooncology 9 2007 581 582
59. L.W. Buie, and J. Valgus Bevacizumab: a treatment option for recurrent glioblastoma multiforme Ann Pharmacother 42 2008 1486 1490
60. P.H. Gutin, F.M. Iwamoto, and K. Beal Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas Int J Radiat Oncol Biol Phys 2009
61. Niyazi M, Ganswindt U, Schwarz SB, et al. Irradiation and bevacizumab in high-grade glioma re-treatment settings. Int J Radiat Oncol Biol Phys 2010; doi:10.1016/j.ijrobp.2010.09.002.
62. P.K. Sneed, M.W. McDermott, and P.H. Gutin Interstitial brachytherapy procedures for brain tumors Semin Surg Oncol 13 1997 157 166 (Pubitemid 27188347)
63. N. Tselis, C. Kolotas, and G. Birn CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results Strahlenther Onkol 183 2007 563 570 (Pubitemid 47482157)
64. S. Patel, J.C. Breneman, and R.E. Warnick Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme Neurosurgery 46 2000 1123 1128 [discussion 1128-1130] (Pubitemid 30249942)
65. J. Julow, A. Viola, K. Balint, and G.T. Szeifert Image fusion-guided stereotactic iodine-125 interstitial irradiation of inoperable and recurrent gliomas Prog Neurol Surg 20 2007 303 311
66. J.B. Halligan, K.J. Stelzer, R.C. Rostomily, A.M. Spence, T.W. Griffin, and M.S. Berger Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas Int J Radiat Oncol Biol Phys 35 1996 541 547 (Pubitemid 126745220)
67. A.J. Gabayan, S.B. Green, and A. Sanan GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis Neurosurgery 58 2006 701 709 [discussion 701-709]
68. J.T. Payne, W.H. St Clair, and C.A. Given 2nd, Young, B, Meigooni, A. Double balloon GliaSite in the management of recurrent glioblastoma multiforme South Med J 98 2005 957 958
69. T.A. Chan, J.D. Weingart, and M. Parisi Treatment of recurrent glioblastoma multiforme with gliasite brachytherapy Int J Radiat Oncol Biol Phys 62 2005 1133 1139 (Pubitemid 40884428)
70. A. Casaco, G. Lopez, and I. Garcia Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma Cancer Biol Ther 7 2008 333 339 (Pubitemid 351847044)
71. A.N. Mamelak, S. Rosenfeld, and R. Bucholz Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma J Clin Oncol 24 2006 3644 3650 (Pubitemid 46630539)
72. A. Boiardi, M. Bartolomei, and A. Silvani Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma J Neurooncol 72 2005 125 131 (Pubitemid 40796462)
73. 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV) Nuklearmedizin 41 2002 120 128 (Pubitemid 34664353)
74. K. Hopkins, V. Papanastassiou, and J.T. Kemshead The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates Recent Results Cancer Res 141 1996 159 175
75. K. Hopkins, C. Chandler, J. Eatough, T. Moss, and J.T. Kemshead Direct injection of 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose Int J Radiat Oncol Biol Phys 40 1998 835 844 (Pubitemid 28150801)
76. R. Henriksson, J. Capala, and A. Michanek Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA) Radiother Oncol 88 2008 183 191
77. T. Yamamoto, K. Nakai, and T. Kageji Boron neutron capture therapy for newly diagnosed glioblastoma Radiother Oncol 91 2009 80 84
78. K.A. Carson, S.A. Grossman, J.D. Fisher, and E.G. Shaw Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials J Clin Oncol 25 2007 2601 2606
79. S. Miyatake, S. Kawabata, and K. Yokoyama Survival benefit of boron neutron capture therapy for recurrent malignant gliomas J Neurooncol 91 2009 199 206
80. E.T. Wong, K.R. Hess, and M.J. Gleason Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 1999 2572 2578
81. M. Brada, K. Hoang-Xuan, and R. Rampling Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse Ann Oncol 12 2001 259 266 (Pubitemid 32223879)
82. W.K. Yung, R.E. Albright, and J. Olson A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 2000 588 593 (Pubitemid 30636298)
83. W.K. Yung, M.D. Prados, and R. Yaya-Tur Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group J Clin Oncol 17 1999 2762 2771 (Pubitemid 29415233)
84. A.A. Brandes, M. Ermani, and U. Basso Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study Oncology 63 2002 38 41 (Pubitemid 34977935)
85. A. Wick, C. Pascher, and W. Wick Rechallenge with temozolomide in patients with recurrent gliomas J Neurol 256 2009 734 741
86. A. Wick, J. Felsberg, and J.P. Steinbach Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma J Clin Oncol 25 2007 3357 3361 (Pubitemid 47325623)
87. A.A. Brandes, A. Tosoni, and G. Cavallo Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) Br J Cancer 95 2006 1155 1160 (Pubitemid 44658477)
88. D.S. Kong, J.I. Lee, and W.S. Kim A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma Oncol Rep 16 2006 1117 1121
89. C. Balmaceda, D. Peereboom, and S. Pannullo Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas Cancer 112 2008 1139 1146 (Pubitemid 351304600)
90. H.S. Friedman, S.T. Keir, and P.J. Houghton The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors Cancer 97 2003 2359 2362
91. J.A. Quinn, S.X. Jiang, and D.A. Reardon Phase 1 trial of temozolomide plus irinotecan plus O-6-benzylguanine in adults with recurrent malignant glioma Cancer 115 2009 2964 2970
92. M.L. Gruber, and W.P. Buster Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma Am J Clin Oncol 27 2004 33 38 (Pubitemid 38176289)
93. A. Silvani, M. Eoli, and A. Salmaggi Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients J Neurooncol 66 2004 203 208 (Pubitemid 38258376)
94. A.A. Brandes, U. Basso, and M. Reni First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia J Clin Oncol 22 2004 1598 1604 (Pubitemid 41079797)
95. F. Paulsen, W. Hoffmann, and G. Becker Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide J Cancer Res Clin Oncol 125 1999 411 418 (Pubitemid 29287500)
96. M.D. Groves, V.K. Puduvalli, and S.M. Chang A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme J Neurooncol 81 2007 271 277
97. A. Boiardi, M. Eoli, and A. Salmaggi Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma J Neurooncol 75 2005 215 220 (Pubitemid 41819728)
98. S.L. Chua, M.A. Rosenthal, and S.S. Wong Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme Neuro Oncol 6 2004 38 43 (Pubitemid 38139638)
99. K.A. Jaeckle, K.R. Hess, and W.K. Yung Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study J Clin Oncol 21 2003 2305 2311
100. D. Afra, L. Sipos, and D. Vitanovics Chemotherapy of recurrent supratentorial malignant gliomas (phase II study) Ideggyogy Sz 55 2002 38 44
101. C. Happold, P. Roth, and W. Wick ACNU-based chemotherapy for recurrent glioma in the temozolomide era J Neurooncol 92 2009 45 48
102. B. Rajan, G. Ross, and C.C. Lim Survival in patients with recurrent glioma as a measure of treatment efficacy - prognostic factors following nitrosourea chemotherapy Eur J Cancer 30A 1994 1809 1815 (Pubitemid 24377157)
103. M. Weller, B. Muller, R. Koch, M. Bamberg, and P. Krauseneck Neuro-Oncology Working Grp German, C. Neuro-oncology working group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma J Clin Oncol 21 2003 3276 3284 (Pubitemid 46606261)
104. M. Glas, T. Hundsberger, and M. Stuplich Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma Oncology 76 2009 184 189
105. L.G. Feun, A. Marini, and H. Landy Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors J Neurooncol 82 2007 177 181 (Pubitemid 46431862)
106. F. Schmidt, J. Fischer, U. Herrlinger, K. Dietz, J. Dichgans, and M. Weller PCV chemotherapy for recurrent glioblastoma Neurology 66 2006 587 589 (Pubitemid 43739895)
107. A.C. Kappelle, T.J. Postma, and M.J. Taphoorn PCV chemotherapy for recurrent glioblastoma multiforme Neurology 56 2001 118 120 (Pubitemid 32059666)
108. M.C. Chamberlain, and D.D. Tsao-Wei Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme Cancer 100 2004 1213 1220
109. A. Ameri, M. Poisson, L. Chauveinc, Q.M. Chen, and J.Y. Delattre Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study J Neurooncol 32 1997 155 160 (Pubitemid 27077984)
110. L.S. Ashby, and W.R. Shapiro Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study J Neurooncol 51 2001 67 86
111. T. Beppu, Y. Yoshida, and H. Arai A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas J Neurooncol 49 2000 213 218 (Pubitemid 32106783)
112. A.A. Brandes, A. Tosoni, and U. Basso Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) J Clin Oncol 22 2004 4779 4786 (Pubitemid 41185089)
113. A.A. Brandes, A. Tosoni, and E. Franceschi Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) Cancer Chemother Pharmacol 64 2009 769 775
114. X. Durando, E. Thivat, and H. Roche Cystemustine in recurrent high grade glioma J Neurooncol 79 2006 33 37 (Pubitemid 44057413)
115. T.F. Cloughesy, E. Filka, and J. Kuhn Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen Cancer 97 2003 2381 2386 (Pubitemid 36444049)
116. T.F. Cloughesy, E. Filka, and G. Nelson Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen Am J Clin Oncol 25 2002 204 208 (Pubitemid 34293080)
117. D.J. Stewart, M.T. Richard, and B. Benoit Cisplatin plus cytosine arabinoside in adults with malignant gliomas J Neurooncol 2 1984 29 34 (Pubitemid 14148612)
118. D. Macdonald, G. Cairncross, and D. Stewart Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group Ann Oncol 7 1996 205 207 (Pubitemid 26340689)
119. J.M. Pipas, L.P. Meyer, and C.H. Rhodes A phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma J Neurooncol 71 2005 301 305
120. P. Khosla Monga 2009 V Taaca, A. Pilot study of topotecan and thalidomide in patients with recurrent malignant gliomas. ASCO Annual Meeting.
121. M. Sanson, A. Ameri, and A. Monjour Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study Eur J Cancer 32A 1996 2229 2235 (Pubitemid 27008495)
122. S.M. Chang, N.A. Butowski, P.K. Sneed, and I.V. Garner Standard treatment, experimental targeted drug therapy for recurrent glioblastoma multiforme Neurosurg Focus 20 2006 E4
123. A.L. Schwer, D.M. Damek, and B.D. Kavanagh A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas Int J Radiat Oncol Biol Phys 70 2008 993 1001
124. M. Preusser, E. Gelpi, and A. Rottenfusser Epithelial growth factor receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study J Neurooncol 89 2008 211 218
125. B. Neyns, and J. Sadones Joosens 2008 E et al. A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma. ASCO Annual Meeting.
126. J.F. de Groot, M.R. Gilbert, and K. Aldape Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma J Neurooncol 90 2008 89 97
127. P. Wen, J. Kuhn, and S. Chang Phase I/II study of erlotinib and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02) Neurooncology 10 2008 824-824
128. M.D. Prados, K.R. Lamborn, and S. Chang Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma Neuro Oncol 8 2006 67 78 (Pubitemid 43154453)
129. B.J. Giantonio Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings Semin Oncol 33 2006 S15 S18
130. E.S. Han, and B.J. Monk Bevacizumab in the treatment of ovarian cancer Expert Rev Anticancer Ther 7 2007 1339 1345
131. S. Ramalingam, and C.P. Belani Role of bevacizumab for the treatment of non-small-cell lung cancer Future Oncol 3 2007 131 139 (Pubitemid 46592720)
132. Gilbert MR, Wang M, Aldape K, et al. RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). ASCO Annual Meeting; 2009.
133. H.S. Poulsen, K. Grunnet, and M. Sorensen Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours Acta Oncol 48 2009 52 58
134. F. Bokstein, S. Shpigel, and D.T. Blumenthal Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors Cancer 112 2008 2267 2273 (Pubitemid 351628638)
135. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon 2nd Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 2007 1253 1259 (Pubitemid 46424067)
136. Raizer JJ, Grimm S, Rice L, et al. A phase II trial of single-agent bevacizumab given every 3 weeks for recurrent malignant gliomas. ASCO Annual Meeting; 2009.
137. Reardon D, Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Norfleet JA. Bevacizumab plus etoposide among recurrent malignant glioma patients: phase II study final results. ASCO Annual Meeting; 2009.
138. E.C. Quant, A.D. Norden, and J. Drappatz Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab Neurooncology 2009
139. A. Morabito, M. Fanelli, G. Carillio, D. Gattuso, R. Sarmiento, and G. Gasparini Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma Oncol Rep 11 2004 93 95
140. V.K. Puduvalli, P. Giglio, and M.D. Groves Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neurooncology 10 2008 216 222
141. S. Kesari, D. Schiff, and L. Doherty Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults Neurooncology 9 2007 354 363 (Pubitemid 47169667)
142. Herndon J, Vredenburgh J, Reardon D, et al. Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. ASCO Annual Meeting; 2009.
143. D.A. Reardon, M.J. Egorin, and A. Desjardins Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma Cancer 115 2009 2188 2198
144. Frentzas SN, Groves MD, Barriuso J, et al. Pazopanib and lapatinib in patients with relapsed malignant glioma: results of a phase I/II study. ASCO Annual Meeting; 2009.
145. D. Mahalingam, K. Sankhala, A. Mita, F.J. Giles, and M.M. Mita Targeting the mTOR pathway using deforolimus in cancer therapy Future Oncol 5 2009 291 303
146. H.F. Li, J.S. Kim, and T. Waldman Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells Radiat Oncol 4 2009 43
147. E. Galanis, K.A. Jaeckle, and M.J. Maurer Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study J Clin Oncol 27 2009 2052 2058
148. T.F. Cloughesy, J. Kuhn, and H.I. Robins Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study J Clin Oncol 23 2005 6647 6656 (Pubitemid 46190259)
149. T.F. Cloughesy, P.Y. Wen, and H.I. Robins Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study J Clin Oncol 24 2006 3651 3656
150. S. Phuphanich, K.A. Carson, and S.A. Grossman Phase I safety study of
151. L.B. Nabors, T. Mikkelsen, and S.S. Rosenfeld Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma J Clin Oncol 25 2007 1651 1657 (Pubitemid 46797943)
152. D.A. Reardon, K.L. Fink, and T. Mikkelsen Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J Clin Oncol 26 2008 5610 5617
153. A. Boiardi, M. Eoli, and A. Salmaggi Local drug delivery in recurrent malignant gliomas Neurol Sci 26 2005 S37 S39 (Pubitemid 40637366)
154. S.H. Lin, and L.R. Kleinberg Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies Expert Rev Anticancer Ther 8 2008 343 359
155. F.J. Attenello, D. Mukherjee, and G. Datoo Use of gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience Ann Surg Oncol 15 2008 2887 2893
156. M.G. Hart, R. Grant, R. Garside, G. Rogers, M. Somerville, and K. Stein Chemotherapeutic wafers for High Grade Glioma Cochrane Database Syst Rev 2008 CD007294
157. J.M. Gallego, J.A. Barcia, and C. Barcia-Marino Fatal outcome related to carmustine implants in glioblastoma multiforme Acta Neurochir (Wien) 149 2007 261 265 [discussion 265] (Pubitemid 46365422)
158. J.J. Olson, E. McKenzie, M. Skurski-Martin, Z. Zhang, D. Brat, and S. Phuphanich Analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme J Neurooncol 90 2008 293 299
159. B.J. Darakchiev, R.E. Albright, J.C. Breneman, and R.E. Warnick Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme J Neurosurg 108 2008 236 242
160. S. Kunwar, M.D. Prados, and S.M. Chang Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group J Clin Oncol 25 2007 837 844 (Pubitemid 350002884)
161. S.S. Stylli, and A.H. Kaye Photodynamic therapy of cerebral glioma - a review. Part II - clinical studies J Clin Neurosci 13 2006 709 717 (Pubitemid 44354170)
162. H. Kostron, A. Obwegeser, and R. Jakober Photodynamic therapy in neurosurgery: a review J Photochem Photobiol B 36 1996 157 168 (Pubitemid 27011261)
163. T.J. Beck, F.W. Kreth, and W. Beyer Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX Lasers Surg Med 39 2007 386 393 (Pubitemid 47041087)
164. S. Krishnamurthy, S.K. Powers, P. Witmer, and T. Brown Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors Lasers Surg Med 27 2000 224 234 (Pubitemid 32511215)
165. S.J. Madsen, C.H. Sun, B.J. Tromberg, and H. Hirschberg Repetitive 5-aminolevulinic acid-mediated photodynamic therapy on human glioma spheroids J Neurooncol 62 2003 243 250 (Pubitemid 36591959)
166. P.J. Muller, and B.C. Wilson Photodynamic therapy for recurrent supratentorial gliomas Semin Surg Oncol 11 1995 346 354
167. S.L. Eck, J.B. Alavi, and K. Judy Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial Hum Gene Ther 12 2001 97 113 (Pubitemid 32044471)
168. S. Harrow, V. Papanastassiou, and J. Harland HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival Gene Ther 11 2004 1648 1658 (Pubitemid 39530101)
169. J.M. Markert, P.G. Liechty, and W. Wang Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM Mol Ther 17 2009 199 207
170. A.D. Norden, J. Drappatz, and A. Muzikansky An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma J Neurooncol 92 2009 149 155
171. Wick W, Weller M, van den Bent M, Stupp R. Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 2010;28:e188-189 [author reply e190-182].
172. A.D. Norden, G.S. Young, and K. Setayesh Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 2008 779 787
173. D. Ishii, A. Natsume, and T. Wakabayashi Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas Neurol Med Chir (Tokyo) 47 2007 341 349 [discussion 350] (Pubitemid 47328144)
174. M. Weller, R. Stupp, and G. Reifenberger MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2009
175. R. Bartsch, H.D. Weitmann, and W. Pennwieser Retrospective analysis of re-irradiation in malignant glioma: a single-center experience Wien Klin Wochenschr 117 2005 821 826 (Pubitemid 43205691)